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ABSTRACT
Mesenchymal stem cells (MSCs) are appealing as gene ther-
apy cell vehicles given their ease of expansion and transduc-
tion. However, MSCs exhibit immunomodulatory and
proangiogenic properties that may pose a risk in their use in
anticancer therapy. For this reason, we looked for a strategy
to conﬁne MSCs to a determined location, compatible with a
clinical application. Human MSCs genetically modiﬁed to
express luciferase (MSC
luc), seeded in a synthetic extracellu-
lar matrix (sECM) scaffold (sentinel scaffold) and injected
subcutaneously in immunodeﬁcient mice, persisted for more
than 40 days, as assessed by bioluminescence imaging in vivo.
MSCs modiﬁed to express a bispeciﬁc a-carcinoembryonic
antigen (aCEA)/aCD3 diabody (MSC
dAb) and seeded in an
sECM scaffold (therapeutic scaffolds) supported the release
of functional diabody into the bloodstream at detectable levels
for at least 6 weeks after implantation. Furthermore, when
therapeutic scaffolds were implanted into CEA-positive
human colon cancer xenograft-bearing mice and human T
lymphocytes were subsequently transferred, circulating
aCEA/aCD3 diabody activated T cells and promoted tumor
cell lysis. Reduction of tumor growth in MSC
dAb-treated
mice was statistically signiﬁcant compared with animals that
only received MSC
luc. In summary, we report here for the
ﬁrst time that human MSCs genetically engineered to secrete
a bispeciﬁc diabody, seeded in an sECM scaffold and
implanted in a location distant from the primary tumor,
induce an effective antitumor response and tumor regression.
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INTRODUCTION
Bone marrow-derived mesenchymal stem cells (MSCs) are
multipotent adult stem cells of mesodermal origin localized
within the bone marrow compartment. MSCs have generated
a great deal of interest for their potential use in regenerative
medicine and tissue engineering because of the ease of their
isolation and their extensive expansion rate and differentiation
potential. MSCs have been used for tissue repair, including
cerebral and spinal cord injury, bone damage, myocardial is-
chemia/infarction, and muscular dystrophy; in the engraftment
of hematopoietic stem cells (HSCs); and in the reduction of
graft-versus-host disease [1, 2].
Furthermore, MSCs can be easily transduced with viral
vectors to be used as cellular vehicles in gene therapy proto-
cols [3]. The extended life span of MSCs makes them espe-
cially interesting as cell factories for the production of thera-
peutic proteins. In cancer therapy approaches, MSCs have
been used for tumor delivery of immunostimulatory cytokines
and chemokines (interferon [IFN]-a [4], IFN-b [5–8], interleu-
kin [IL]-2 [9], IL-12 [10, 11], and CX3CL1 [12]), suicide
genes (thymidine kinase [13] and cytosine deaminase [14]),
growth factor antagonists (NK4) [15], and oncolytic viruses
[16, 17] after systemic administration, taking advantage of
their tumor-homing capacities, or by intratumoral inoculation.
However, recent evidence also suggests that they could
play a role in tumor growth and metastasis [18]. The immuno-
suppressive [19–22] and proangiogenic properties [23] of
MSCs may be responsible, at least in part, for their effects on
cancer development. This implies a potential risk in the use
of MSCs in cell-based anticancer therapies [24], especially
when MSCs are inoculated in the vicinity of tumor cells or
allowed to migrate toward them.
In fact, for strategies where cells are used as therapeutic
factories, their ability to disseminate throughout the body is
not required, or is even undesirable. Producer cells can be
conﬁned to scaffolds that keep cells at the implantation site,
although the therapeutic protein may act at distance if
secreted into circulation [25]. Subcutaneous delivery of MSCs
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retrieved once the therapeutic effect is fulﬁlled. It has been
reported that matrix-embedded MSCs, genetically modiﬁed to
produce erythropoietin (EPO) and subcutaneously inoculated
in a mouse model of anemia, supported the release of the pro-
tein into the bloodstream for a sustained pharmacological
effect [26, 27].
Recently, this approach was used in a breast cancer model
for the delivery of IL-12 by murine MSCs embedded in a bo-
vine collagen-based matrix [28]. Interestingly, even though
plasma of mice that received the IL-12 MSC-containing sub-
cutaneous implants showed increased levels of IL-12, there
was no therapeutic effect when IL-12 MSCs were not admin-
istered in the same location as tumor cells. This requirement
poses a clear limitation for the translation of this approach to
a clinical setting and implies the risk of potential MSC contri-
bution to tumor growth.
In previous works we have demonstrated the antitumoral
effect of a bispeciﬁc anticarcinoembryonic antigen (a-CEA)
  anti-CD3 (aCD3) diabody secreted in autocrine fashion by
gene modiﬁed human primary T lymphocytes. Secreted
aCEA/aCD3 diabody on tumor site induced T-cell activation
and tumor growth inhibition in vivo [29, 30]. However, the
short life span of activated human T lymphocytes and their
inefﬁcient transduction constitute important drawbacks for
their application in cancer therapy. Alternatively, we decided
to explore the potential of human MSCs as diabody producer
cells in a human tumor xenograft. First, we studied the immu-
nomodulatory properties of MSCs in our model to rule out
any counterproductive effect. Conditioned medium from
MSCs inhibited T-cell proliferation in vitro, and what is
more, coimplantation of tumor cells and MSCs signiﬁcantly
promoted tumor growth in vivo. To avoid any contact with
immune effectors or tumor cells, diabody-producing MSCs
were embedded in a nonimmunogenic synthetic extracellular
matrix (sECM) scaffold and inoculated in the ventral subcuta-
neous space of nude mice. Diabody was released into the
bloodstream at detectable levels and inhibited the growth of
human cancer cells subcutaneously inoculated in the dorsal
region in the presence of systemically administered human T
lymphocytes. In summary, we report here for the ﬁrst time
the use of human MSCs genetically engineered for the pro-
duction of a bispeciﬁc diabody, seeded in an sECM scaffold
and subcutaneously implanted in immunodeﬁcient mice, to
demonstrate the systemic antitumoral effect of a therapeutic
antibody locally produced.
MATERIALS AND METHODS
Human Mesenchymal Stem Cells Isolation
and Culture Conditions
Human MSCs were obtained from bone marrow samples from
healthy donors after informed consent. MSCs were puriﬁed and
expanded as previously described [21]. Purity of MSCs was
tested by ﬂow cytometry on a Epics XL ﬂow cytometer (Beck-
man Coulter, Hialeah, FL, http://www.beckmancoulter.com) using
the following monoclonal antibodies (mAbs): CD45-ECD (clone
J33), CD31-ﬂuorescein isothiocyanate (FITC) (clone 5.6E),
CD34-PC5 (clone 581), CD90-PE (clone Thy1/310) (Beckman
Coulter), major histocompatibility complex (MHC)-class I-FITC
(clone W6/32), CD14-FITC (clone UCHM-1) (both from Sigma-
Aldrich, St. Louis, http://www.sigmaaldrich.com), CD13-PE
(clone L138), CD73-PE (clone AD2) (both from BD Biosciences,
Erembodegen, Belgium, http://www.bdbiosciences.com), and
CD105-PE (clone SN6) (eBioscience Inc., San Diego, http://
www.ebioscience.com). MSCs were used for experiments
between the third and fourth passages.
Human Hematopoietic Stem Cells Isolation
and Culture Conditions
Human HSCs were obtained from umbilical cord blood with
informed consent and processed within 24 hours. Mononuclear
cells were separated by density gradient centrifugation. CD34
þ
cell subpopulation was isolated using the MultiSort MicroBeads
conjugated to anti-human CD34 mAb (clone QBEND/10) (Milte-
nyi Biotec, Bergisch Gladbach, Germany, http://www.miltenyibio-
tec.com) according to the manufacturer’s instructions. Cells were
stained with the following mAbs: CD38-FITC (clone HIT2)
(Immunotools, Friesoythe, Germany), CD133-PE (clone AC133)
(Miltenyi Biotec), CD45-ECD (clone J33), and CD34-PC5 (clone
581) (both obtained from Immunotech), and analyzed by ﬂow
cytometry. Approximately 5   10
4 HSCs were cultured in 24-
well plates with StemSpan SFEM Medium (Stem Cell Technolo-
gies, Vancouver, BC, Canada, http://www.stemcell.com) supple-
mented with a cytokine cocktail consisting of 50 ng/ml thrombo-
poietin, 20 ng/ml interleukin-6, 50 ng/ml stem cell factor, and 50
ng/ml ﬂk-2/ﬂt3 ligand (all recombinant human cytokines were
from Peprotech, London, http://www.peprotech.com).
Human Primary Peripheral Blood Lymphocytes
Isolation and In Vitro Expansion
Human peripheral blood lymphocytes (PBLs) were isolated from
healthy donors peripheral blood by density gradient centrifuga-
tion. Cells were expanded with Dynabeads CD3/CD28 (Dynal
Biotech, Oslo, Norway, http://www.invitrogen.com/dynal) accord-
ing to the manufacturer’s instructions, in the presence of 100 U/
ml interleukin-2 (Sigma-Aldrich). The phenotype of PBLs before
and after culture was determined by ﬂow cytometry using the fol-
lowing mAbs: CD45-FITC (clone B3821F4A), CD4-RD1 (clone
SFC112T4D11), CD8-ECD (clone SFCI21Thy2D3), CD3PC5
(clone UCHT1) (Beckman Coulter), and CD56-PE (clone
NCAM16.2) (BD Biosciences).
Cell Lines
HEK-293 (human embryo kidney epithelia; CRL-1573) and its
derivative 293T (CRL-11268) cells, HCT-116 (human colon car-
cinoma; CCL-247), HeLa (human cervix adenocarcinoma; CCL-
2), and IMR90 (human lung ﬁbroblast; CCL-186) cells were
grown in Dulbecco’s modiﬁed Eagle’s medium (DMEM) supple-
mented with 10% heat-inactivated fetal calf serum (FCS), 2 mM
L-glutamine, and penicillin/streptomycin (all from Invitrogen,
Carlsbad, CA, http://www.invitrogen.com). All of these cells lines
were obtained from the American Type Culture Collection (Rock-
ville, MD, http://www.atcc.org). The HeLa
CEA cell line [31] was
cultured in medium containing 750 lg/ml G418 (Promega, Madi-
son, WI, http://www.promega.com).
Lentiviral Vectors and Cell Transduction
The transfer vector pRRL-IRES-EGFP contains a cytomegalovi-
rus promoter that drives an enhanced green ﬂuorescent protein
(EGFP) expression cassette, the vector pRRL.dAb.EGFP drives
the expression of a bispeciﬁc aCEA/aCD3 diabody and EGFP,
and the vector pRRL-Luc-IRES-EGFP drives the expression of
luciferase and EGFP [23, 29, 30]. Lentiviral particles were pro-
duced by cotransfection of 293T cells through the calcium phos-
phate precipitation method [30]. Human stem cells (MSCs and
HSCs), HCT-116 cells, and HEK-293 cells (1   10
5) were
seeded in six-well plates and infected overnight with lentivirus
stocks (Lenti
EGFP, Lenti
dAb, or Lenti
Luc) at a ﬁnal multiplicity of
infection (MOI) of 15. After 16 hours medium was replaced, and
cells were cultured for 48 hours. EGFP transgene expression was
monitored by ﬂow cytometry. Conditioned media from either
HSCs, MSCs, or HEK-293 cells transduced with Lenti
dAb
(HSC
dAb, MSC
dAb, or 293
dAb) were analyzed for aCEA/aCD3
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(ELISA) as described [30].
T Lymphocyte Proliferation Assays
Human PBLs (10
5 cells per well) were plated in triplicate in 100 ll
of complete medium in ﬂat bottom 96-well plates, precoated (10
lg/ml) with anti-CD3 mAb (clone UCHT1; BD Biosciences). Then
100 ll of fresh medium or cell-free conditioned medium (CM)
from 48-hour cultures of either MSCs (CM-MSC) or HEK-293
cells (CM-293) was added. After 72 hours cell proliferation was an-
alyzed by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
(MTT) assay (Promega). Diabody-induced T lymphocyte prolifera-
tion assays were performed in triplicate in ﬂat bottom 96-well
plates. Human T lymphocytes (10
5 cells per well) were cocultured
with previously irradiated target cells [29] (HeLa or HeLa
CEA)a t
an effector/target ratio of 5:1 in the presence of fresh medium or
CM from 48-hour cultures of either lentivirally transduced HEK-
293 cells or MSCs (293
EGFP or MSC
dAb). After 72 hours, prolifera-
tion was analyzed by the MTT assay.
In Vivo Bioluminescence Imaging
Mice were imaged using the ORCA-2BT high-resolution, charge-
coupled device cooled digital camera (Hamamatsu Photonics
France, Massy, France, http://www.hamamatsu.com) and Wasabi
software (Hamamatsu Photonics). Animals were injected intra-
peritoneally (i.p.) with 125 mg/kg (150-200 ll) D-luciferin (Prom-
ega) 10 minutes prior to imaging. Bioluminescence imaging
(BLI) was collected with a 1-minute integration time, and pseu-
docolor representations of light intensity were superimposed over
the grayscale reference image acquired at low light (exposure
time, 20 milliseconds). An average of six kinetic BLI acquisitions
were collected after substrate injection to conﬁrm a peak of pho-
ton emission. For quantiﬁcation of the detected light, regions of
interest were drawn, and the light emitted from each region was
assessed by recording the total number of photons per second
(total ﬂux) after background subtraction.
In Vivo Effect of MSCs on Tumor Growth
We established a xenograft model in which HCT-116 tumor cells
(2   10
6) were mixed, in a proportion of 4:1, with luciferase-
expressing human MSCs (MSCs
Luc) and injected subcutaneously
(s.c.) into the dorsal space of 5-week-old female athymic nude
mice (Hsd: athymic Nude/Nude; Harlan Ibe ´rica, Barcelona, Spain,
http://www.harlan.com). The growth kinetics of the MSC-contain-
ing HCT-116 tumors was compared with those of HCT-116
injected alone. Tumor volumes were determined at various time
points using the formula width
2   length   0.52. All mice were
handled in accordance with the guidelines of Institutional Animal
Care and Use Committee and performed in accordance with
Spanish legislation.
Tumor Cell Proliferation In Vitro
To determine the effect of CM from MSCs or normal human
IMR90 ﬁbroblasts on tumor cell proliferation in vitro, MSCs and
IMR90 cells were cultured as described previously, and after
48 hours, the medium was collected and ﬁltered. DMEM supple-
mented with 10% heat-inactivated FCS was used as control.
HCT-116 cells (1.4   10
4) were plated in triplicate in a 96-well
plate and permitted to adhere, after which the culture medium
was exchanged with CM containing 10% FCS. Proliferation was
measured by an MTT assay at 4, 24, 48, and 72 hours.
MSC-Seeded Scaffold Implantation
Either MSC
dAb or MSC
Luc (1   10
6) were seeded in two differ-
ent 90% synthetic hydrogel solutions, Extracel-X [32, 33] or
Extracel-HP [34] (Glycosan BioSystems, Salt Lake City, http://
www.glycosan.com), to obtain either MSC
dAb- or MSC
Luc-seeded
scaffolds. MSC-seeded scaffolds were supplemented with 128 U/
ml heparin (Sigma-Aldrich), 50 ng/ml human vascular endothelial
growth factor, and 150 ng/ml human basic ﬁbroblast growth fac-
tor (both from Peprotech) and were contralaterally implanted s.c.
in the ventral area. To assess the secretion of diabody by
MSC
dAb, mice were bled by retro-orbital puncture at regular time
points, and plasma concentration was determined by ELISA [30].
Antitumoral Effect of MSC
dAb-Seeded
Scaffolds In Vivo
Luciferase-expressing HCT-116 tumor cells (HCT-116
Luc) were
inoculated s.c. into the dorsal space of nude mice as described
above. Five days after tumor implantation, one group of mice
received MSCs
Luc-seeded scaffolds (sentinel scaffold) and
MSC
dAb-seeded scaffolds (therapeutic scaffold) injected s.c. in
opposite ﬂanks in the ventral area. Another group (control group)
received only the MSC
Luc-seeded scaffolds. Two days later, mice
received i.v. injection (i.v.) of human T lymphocytes (2   10
6).
MSC-seeded scaffolds and tumors were retrieved, ﬁxed with 10%
formalin, and parafﬁn-embedded. Sections were stained with he-
matoxylin and eosin.
Statistical Analysis
The SPSS v.14.0 software program (SPSS, Chicago, http://
www.spss.com) was used for statistical analysis. The analysis of
variance repeated measures model was used for compute the sta-
tistical signiﬁcance of differences between groups. All p values
were two-sided, and values of .05 or less were considered to indi-
cate statistical signiﬁcance.
Quantitative Analyses of Tumor Vascularization
Tumors were excised at day of sacriﬁce and were formalin-ﬁxed
and parafﬁn-embedded. A histological section from each xeno-
graft was stained with hematoxylin and eosin according to stand-
ard protocols. Sections were ﬁrst scanned at low magniﬁcation
( 5) to identify vascular structures. Areas of vessel density were
then examined under higher magniﬁcation ( 40) and counted
[35]. Vascularization was quantiﬁed by enumerating the mature
vessels in four randomly chosen ﬁelds and expressing the mean
  SD obtained for each condition.
RESULTS
Comparison of Human Hematopoietic and
Mesenchymal Stem Cells Transduced with a
Lentiviral Vector Encoding a Bispeciﬁc
aCEA/aCD3 Diabody
The extended life span of stem cells makes them attractive as
cell factories for the production of therapeutic antibodies. We
wanted to compare the potential as antibody producer cells of
lentivirally transduced human HSCs and MSCs. HSCs were
isolated from human umbilical cord blood using human CD34
microbeads and characterized by ﬂow cytometry analysis.
More than 90% of puriﬁed HSCs exhibited the phenotype
CD34
þCD38
lowCD133
þCD45
low (supporting information Fig.
1A). MSCs, obtained from human bone marrow as previously
described [23], displayed a characteristic phenotype, with
prominent expression of CD13, CD73, CD90, CD105, and
MHC-class I, whereas CD31, CD34, and CD45 were absent
(supporting information Fig. 1B).
We transduced both human HSCs and MSCs with a VSV-
G pseudotyped lentiviral vector encoding an aCEA/aCD3 dia-
body (Lenti
dAb) [30] at an MOI of 10 to produce, respec-
tively, HSC
dAb and MSC
dAb. Flow cytometry analysis (Fig.
1A) revealed that the expression of EGFP was remarkably
higher in MSCs than in HSCs. Secretion of aCEA/aCD3 dia-
body into the cell culture supernatant was assessed by ELISA,
72 hours after stem cell transduction (Fig. 1B). The level of
functional diabody secreted by MSC
dAb (110 ng/ml   10
5
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HSCs
dAb (Fig. 1B). Given that MSCs are markedly more per-
missive to lentiviral transduction, we decide to use MSC
dAb
as diabody producer cells in our immunotherapeutic approach
for cancer therapy.
Next, we evaluated the persistence of transgene expression
by MSC
dAb over time post-transduction. Overall, the percent-
age of MSCs expressing EGFP was maintained, between 80%
and 90%, for 30 days (Fig. 1C). More importantly, the
secretion of functional aCEA/aCD3 diabody remained stable
during this period, with levels of 81 ng/ml   10
5 cells per
72 hours at day 30 (Fig. 1D).
Immunomodulatory Effect of MSCs
on T-Cell Proliferation
To assess the immunomodulatory effect of MSCs, human
PBLs were stimulated by plastic-immobilized anti-CD3 mAb
in the presence of fresh medium or cell-free CM-293 or CM-
MSC. The polyclonal proliferation of T lymphocytes was
roughly two times lower in the presence of CM-MSC than in
the presence of either CM-293 or medium alone (Fig. 2A). As
we have previously demonstrated, locally produced aCEA/
aCD3 diabody is capable of acting as an efﬁcient activating
molecule for T lymphocytes in the presence of CEA-express-
ing tumor cells [28]. Therefore, we performed different cocul-
tures of T lymphocytes with either CEA-positive (HeLa
CEA)
or CEA-negative (HeLa) tumor cells. CM from cultures of ei-
ther HEK-293 or MSCs cells, transduced with Lenti
dAb or
Lenti
EGFP, was added. Diabody-induced T lymphocyte prolif-
eration, in cocultures with HeLa
CEA cells, was approximately
2.5 times lower in the presence of CM-MSC
dAb than in the
presence of CM-293
dAb (Fig. 2B). This difference is not at-
tributable to a higher production of aCEA/aCD3 diabody by
HEK-293 cells, given that levels were comparable in both
CM as assessed by ELISA (data not shown). T lymphocytes
cocultured with HeLa cells did not proliferate, independently
of the source of CM (Fig. 3B). CM from EGFP-transduced
cells had no effect on T-cell proliferation rate.
Effect of MSCs on Tumor Growth
To investigate whether MSCs could exert an effect on tumor
growth in vivo, we compared the growth kinetics of HCT-116
cells (a human colon carcinoma CEA-positive cell line) s.c.
implanted alone (control group) or along with MSCs (ratio
4:1) in nude mice. MSCs had been previously transduced
with luciferase-encoding lentiviral vector (MSCs
Luc) to moni-
tor in vivo their fate within tumors by BLI. Photon emission,
indicating the presence of viable MSCs, was detectable until
day 15 postinoculation (Fig. 3B). The subsequent loss of lu-
ciferase activity signal can be attributed to a dispersion effect
due to increasing tumor volume, and not to a decrease in
MSCs
Luc viability.
In fact, tumor growth in MSC-containing tumors (HCT-
116 þ MSCs
Luc) was remarkably higher than in control mice
(HCT-116 alone); the difference was statistically signiﬁcant
from day 17 postimplantation until the end of the experiment.
At day 40, mean tumor volume in the MSCs
Luc group was
nearly 2.5 times the tumor volume of the control group (p ¼
.001) (Fig. 3A). These results strongly suggested a tumor-pro-
moting effect of MSCs and discouraged us from taking
advantage of their tumor-tropic properties. MSCs were still
appealing as diabody producer cells, but special care should
be taken to avoid close contact with tumor cells.
To understand the mechanism underlying the in vivo pro-
motion of tumor growth by MSCs in our model, we studied
the proliferation of tumor cells in the presence of CM-MSCs.
No signiﬁcant difference in cell numbers could be detected
when compared with HCT-116 cells incubated with fresh me-
dium or CM from human ﬁbroblasts (CM-IMR90) (supporting
information Fig. 2A). Then, we analyzed the effect of MSCs
coimplantation on tumor angiogenesis in vivo. Quantiﬁcation
of microvessels in tumor sections yielded a signiﬁcant
increase in tumors coimplanted with MSCs (supporting
Figure 1. Transduction of HSCs and mesenchymal stem cells (MSCs) with dAb.EGFP-encoding lentivirus (Lenti
dAb) at a multiplicity of infec-
tion of 10. (A, B): Analysis of EGFP expression (A) and secretion of a-CEA/aCD3 diabody into the cell culture supernatant (B) 72 hours after
transduction. (C, D): Transgene expression stability in MSCs (MSC
dAb): expression of EGFP (C) and secretion of a-CEA/aCD3 dAb (D). Abbre-
viations: a-CEA, a-carcinoembryonic antigen; dAb, diabody; EGFP, enhanced green ﬂuorescent protein; HSC, hematopoietic stem cells; MSC,
mesenchymal stem cell; MSC
dAb, mesenchymal stem cells after infection with Lenti
dAb.
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nant transformation could be detected in vivo, we can assume
that the observed enhancement of tumor growth by MSCs in
our model is due to increased tumor angiogenesis.
Establishment of MSCs-Seeded Scaffolds and
Systemic Release of aCEA/aCD3 Diabody
The enhancement of tumor growth and the immunomodula-
tory effect mediated by MSCs are important disadvantages for
their use as therapeutic factories at the tumor site. To over-
come these limitations, MSCs were conﬁned to locations dis-
tant from tumor sites using injectable synthetic hydrogel scaf-
folds. Two different commercially available hydrogel
formulations were tested for their ability to support MSC sur-
vival and engraftment: Extracel-X and Extracel-HP. At day
15 postimplantation of 10
6 cells in nude mice, luciferase ac-
tivity of MSC
Luc seeded in Extracel-X scaffolds was approxi-
mately twofold higher than that of MSC
Luc seeded in
Extracel-HP (supporting information Fig. 3A). More interest-
ingly, systemic diabody levels were three times higher in
mice that received MSC
dAb-seeded Extracel-X scaffolds (sup-
porting information Fig. 3B). Therefore, Extracel-X was cho-
sen for long-term studies of MSC-seeded scaffolds.
MSC
dAb-seeded Extracel-X scaffolds (therapeutic scaf-
folds) were inoculated s.c. in the left ventral area of immuno-
deﬁcient mice. Scaffolds containing the same amount of
MSCs
Luc (sentinel scaffolds) were implanted contralaterally
for the monitoring of MSC engraftment and persistence by
BLI. As shown in Figure 4A, MSCs
Luc-seeded scaffolds
exhibited stable luciferase activity, with a slight decrease by
day 42. Plasma levels of aCEA/aCD3 diabody were deter-
mined by ELISA, yielding concentrations ranging from 145
ng/ml at day 7 to 30 ng/ml 6 weeks after implantation (Fig.
4B). Histological study of MSCs
Luc-seeded scaffolds resected
42 days after implantation revealed the presence of viable cell
embedded in a dense, hematoxylin-stained matrix with no
clearly differentiated architecture (data not shown).
Antitumor Effect of MSCs
dAb-Seeded Scaffolds in a
Human Colon Carcinoma Xenograft Model
To assess the in vivo effect of aCEA/aCD3 diabody secreted
by MSC
dAb on tumor growth, we established xenografts of
the CEA-positive human colon carcinoma cell line HCT-116,
previously transduced with the Lenti
Luc (HCT-116
Luc),
through s.c. inoculation of 10
6 cells in the dorsal region of
nude mice. Five days after tumor cell implantation, two
MSC-seeded scaffolds containing, respectively, MSCs
Luc and
MSC
dAb were implanted in opposite ﬂanks in the ventral area
of the same animals. A control group received only the senti-
nel scaffold. One week after tumor implantation the two
groups of mice received an i.v. injection of 2   10
6
Figure 3. Effect of intratumoral MSCs on human colorectal carci-
noma xenograft growth. (A): Tumor volume measurements of HCT-
116 cells (2   10
6) injected s.c. into nude mice (n ¼ 4 mice per
group) with or without 5   10
5 MSC
Luc. (B): The persistence of via-
ble functional MSC
Luc in the tumors was assessed by biolumines-
cence imaging (BLI). BLI of a representative mouse is shown 2, 7,
15, and 30 days after implantation of HCT-116 and MSC
Luc cells.
Abbreviation: MSC
LUC, mesenchymal stem cells infected with lucifer-
ase-encoding lentivirus.
Figure 2. Inhibitory effect of MSCs on T lymphocyte proliferation.
(A): CM-MSC inhibits the proliferation of human T lymphocytes fol-
lowing polyclonal stimuli. (B): CM-MSC
dAb inhibits the speciﬁc pro-
liferation of T lymphocytes induced by aCEA/aCD3 diabody in
presence of CEA-positive cells. Approximately 10
5 human T lympho-
cytes were stimulated (effector/target ratio ¼ 5:1) with irradiated
CEA-negative (HeLa) or CEA-positive (HeLa
CEA) target cells in the
presence of medium or cell-free conditioned medium from cultures of
HEK-293 or MSCs transduced with either Lenti
EGFP or Lenti
dAb.A s
controls, effector and target cells were cultured alone (data not
shown). Proliferation was analyzed after 72 hours of culture. Abbrevi-
ations: CEA, carcinoembryonic antigen; CM-293, conditioned me-
dium from HEK-293 cells; CM-MSC, conditioned medium from
mesenchymal stem cells; CM-MSC
dAb, CM from mesenchymal stem
cells transduced with Lenti
dAb; dAb, diabody; EGFP, enhanced green
ﬂuorescent protein.
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lymphocytes were CD3
þ: 44% CD3
þCD4
þ and 46%
CD3
þCD8
þ (data not shown).
Tumor volumes (Fig. 5A) were measured over time, and
luciferase activity of HCT-116
Luc (dorsal) and MSCs
Luc (ven-
tral) was monitored by BLI (Fig. 5B and data not shown).
Mice bearing therapeutic scaffolds exhibited consistently
slower tumor growth and showed a statistically signiﬁcant dif-
ference in tumor volume when compared with the control
group containing only sentinel scaffolds (p ¼ .037 at day 40
after tumor inoculation).
DISCUSSION
The availability of antibody genes as cloned material opens
the way for alternative strategies to the passive administration
of high doses of puriﬁed protein. In vivo production of thera-
peutic antibodies by genetically engineered cells may advanta-
geously replace injection of puriﬁed antibodies in cancer
treatment [36, 37]. The feasibility of in vivo production and
systemic delivery of antibodies by different cells has been
demonstrated using different techniques, such as ex vivo ge-
netically modiﬁed autologous cells and in vivo gene transfer
using viral vectors. We have previously shown that human T
lymphocytes, transduced ex vivo to secrete the activating dia-
body aCEA/aCD3 in autocrine fashion, inhibited the growth
of CEA-positive tumors [30]. However, activated T lympho-
cytes possess a short life span, and this implies an obvious
limitation to their application in a gene therapy strategy. In
contrast to terminally differentiated cell types, stem cells are
Figure 4. Establishment and characterization of MSCs-seeded
Extracel-X scaffolds. (A): The persistence of viable functional MSC
Luc
in the scaffolds was assessed by bioluminescence imaging (BLI) 1, 7,
30, and 42 days after implantation. Shown is BLI of a representative
mouse (total, n ¼ 3 mice per group). (B): Plasma concentration of
aCEA/aCD3 diabody in mice implanted with MSC
dAb-embedded scaf-
folds. Abbreviation: aCEA, a-carcinoembryonic antigen.
Figure 5. Human colorectal carcinoma xen-
ograft growth in nude mice bearing MSC
dAb-
seeded scaffold. (A): Tumor volume meas-
urements of HCT-116 cells (2   10
6)
infected with luciferase-encoding lentivirus
(HCT-116
Luc) injected s.c. into the dorsal
skin of nude mice (n ¼ 3 mice per group).
Five days after tumor implantation, MSCs or
MSC
dAb (1   10
6) were seeded in a syn-
thetic extracellular matrix Extracel-X scaf-
fold and inoculated s.c. in the ventral area.
Two days later, animals received an i.v.
injection of 2   10
6 human unfractionated
peripheral blood lymphocytes. (B): Biolumi-
nescence imaging assay for monitoring tumor
growth in vivo, at days 7, 30, and 42 after
tumor implantation. Abbreviations: dAb, dia-
body; MSC, mesenchymal stem cell.
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capacity. For this reason we explored the potential of HSCs,
widely used in therapeutic protocols for genetic diseases, and
MSCs, relatively new in the ﬁeld, as cell factories for diabody
production. In our hands, HSC are difﬁcult to gene-modify,
and the cytokine cocktail used for their expansion is expen-
sive. On the contrary, MSCs are easily transduced and exhibit
a unique in vitro expansion capacity using a simple medium
formulation.
Several works have explored recombinant protein delivery
by genetically engineered MSCs following i.v. administration
or intratumoral inoculation in cancer therapy approaches [4–
15]. However, MSCs have proangiogenic and immunomodula-
tory properties, which raise concern over the safety of their
use in cancer patients [24]. MSCs are known to produce a va-
riety of growth factors that can promote angiogenesis.
Recently, we have corroborated the role of MSCs in an in
vivo model of human angiogenesis, where human endothelial
cells genetically modiﬁed to express luciferase were embed-
ded in a matrix preparation (Matrigel) along with MSCs and
s.c. inoculated in nude mice [23]. The presence of MSCs was
essential for sustained luciferase activity, suggesting a key
role of MSCs in regulating vessel maturation and functional-
ity. More controversy exists over the effect of MSCs on tu-
mor growth: both enhancement and inhibition, as well as no
apparent effect, have been reported [24]. Intriguingly, a recent
study demonstrated a role of MSCs in increasing metastasis
rate, independently of the effect on primary tumor growth. In
this work, MSCs accelerated the growth of MCF7/Ras tumors
without affecting the kinetics of MDA-MB-231 or MDA-MB-
435 tumors, but all of them displayed a marked increase in
the numbers of micro- and macroscopic lung metastases [18].
We tested the effect of MSCs over human T cell-speciﬁc acti-
vation in vitro and tumor growth in vivo and found out that it
could be counterproductive to let MSCs to mix with either
immune effector or tumor cells. MSCs not only inhibited T-
cell proliferation when cocultured with CEA-positive tumor
cells in the presence of aCEA/aCD3 diabody but also signiﬁ-
cantly enhanced tumor growth in vivo. In our model, promo-
tion of tumor growth by MSCs may be attributed to a sup-
portive role in angiogenesis [23, 38]. Consequently, we
searched for a strategy to conﬁne MSCs to a concrete loca-
tion, avoiding dissemination throughout the body.
With this aim, we took advantage of our experience with
the in vivo human angiogenesis model previously described
[23]. Matrigel is a murine basement membrane preparation
constituted by a mixture of extracellular matrix proteins,
widely used in angiogenesis studies in vitro and in vivo, but
probably not best suited for MSC encapsulation in a clinical
setting. We tested different hydrogel formulations, commer-
cially available, that offer several advantages with respect to
Matrigel: they are synthetic, of nonanimal origin, and poten-
tially less immunogenic, and their composition is the same
batch to batch. So we replaced Matrigel with a hydrogel
sECM scaffold speciﬁcally designed for tissue engineering
applications and the one that best supported MSC engraftment
in vivo. This issue was addressed by BLI of MSC
luc-seeded
scaffolds and determination by ELISA of the diabody plasma
levels of mice bearing MSC
dAb-seeded scaffolds. Both
luciferase activity and diabody levels in plasma were
detectable 6 weeks after s.c. implantation of the respective
scaffolds. Safety of implanted cells have recently been tested
in a series of murine MSCs-scaffold combinations, and it was
shown that the implanted cells did not spread to other organs
[39].
A similar approach was described in the study by Elio-
poulos et al. [26], which showed that secretion of an EPO can
be prolonged by embedding the gene-modiﬁed MSCs in
Matrigel before their s.c. delivery. Most interestingly, the
same group recently reported the use of IL-12 producing
MSCs, s.c. implanted, for breast cancer therapy [28]. In this
study, Matrigel was replaced with a viscous bovine collagen-
based matrix. IL-12-producing MSCs implanted in the vicinity
of already present breast cancer tumor led to a signiﬁcant
slowing of cancer growth and to increased survival. These IL-
12-secreting implants supported an increase in systemic levels
of mIL-12, as concentrations were more than 10-fold higher
than in the control mice. Unexpectedly, the observed thera-
peutic effect was not due to systemic IL-12, since IL-12-pro-
ducing MSCs implanted contralaterally did not exert the anti-
tumoral effect. This requirement for MSC implantation at the
tumor site would preclude their use in a clinical setting, given
that human tumors are not easily accessible in general, and
MSC implants would be hardly retrievable afterward.
These results are in clear contrast with those reported
here. In our study immunodeﬁcient mice were used for T-cell
transfer experiments because of the human nature of the anti-
gens recognized by the aCEA/aCD3 diabody. In all of the
experiments, an unfractionated population of human PBLs
(containing CD4þ as well as CD8þ lymphocytes) was used.
Diabody aCEA/aCD3 was produced and secreted into the
bloodstream from a distant location, given that MSC
dAb-
seeded scaffolds were implanted in the ventral region and tu-
mor cells in the dorsal region of nude mice. Circulating dia-
body was able to activate systemically transferred human T
cells for the eradication of CEA-positive tumor cells, resulting
in the overall reduction of tumor growth. The potential of bis-
peciﬁc antibodies in cancer therapy has been extensively
proved in a variety of in vitro and in vivo models, and early
clinical trials have shown safety of these molecules and clini-
cal responses [40].
Nevertheless, the therapeutic potential of exogenously
administered antibodies is limited by their short half-life and
their poor accessibility to tumor sites. Antibody fragments ex-
hibit rapid blood clearance and poor retention time in the tar-
get, which results in the necessity for frequent delivery of
such agents. Genetically engineered cells could be the sources
of sustained concentrations of soluble antibody fragments, ca-
pable of achieving long-term antitumor efﬁcacy. In vivo pro-
duction results in effective and persistent levels of antibody
fragments with a syngenic glycosylation pattern. This com-
pensates for their rapid blood clearance and could make the
antibodies less immunogenic and better tolerated.
SUMMARY
We report here for the ﬁrst time the use of human MSCs ge-
netically engineered for the production of a bispeciﬁc dia-
body, seeded in an sECM scaffold and s.c. implanted in
immunodeﬁcient mice, to demonstrate the systemic antitu-
moral effect of a therapeutic antibody locally produced in a
distant location.
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